Effect of TECAR on Supraspinatus Tendon Thickness in Supraspinatus Tendinitis

Effect of Transfer Energy Capacitive and Resistive Therapy on Supraspinatus Tendon Thickness and Subacromial Space in Supraspinatus Tendinitis

Is the TECAR therapy effective on supraspinatus tendon thickness, sub acromial space, pain intensity , shoulder range of motion, muscle strength ( supraspinatus and middle fiber of deltoid) and functional disabilities in patients with supraspinatus tendinitis?

Supraspinatus tendinitis is a common disorder of the rotator cuff characterized by inflammation and degeneration of the supraspinatus tendon, typically resulting from repetitive overhead activities, mechanical impingement beneath the acromion, or age-related degenerative changes. This condition often leads to shoulder pain, reduced range of motion, and functional impairment during arm elevation and overhead movements. Recently, Studies demonstrated that the addition of TECAR therapy to a standard physiotherapy regimen improves shoulder pain, disability, and passive range of motion in patients with adhesive capsulitis, supporting the use of TECAR as an effective modality in shoulder musculoskeletal rehabilitation.

Inclusion Criteria:

1. Fifty patients with chronic supraspinatus tendinitis on the dominant side.
2. Patients with age range from 18 to 65 years old from both genders.
3. Patients reporting positive empty can test.
4. patients reporting pain with resisted isometric abduction.
5. Patients experiencing shoulder pain for at least 4 weeks.
6. patients reporting pain with active shoulder elevation in the scapular plane.

Exclusion Criteria:

1. Patients with shoulder surgery or trauma in the past 6 months will be excluded.
2. Patients with full-thickness rotator cuff tears, fractures, or severe osteoarthritis will be excluded.
3. Patients with systemic diseases affecting tendon healing (e.g., uncontrolled diabetes, rheumatoid arthritis) will be excluded.
4. Patients who were pregnant or breastfeeding will be excluded.
5. Patients currently receiving other shoulder therapies that could affect outcomes will be excluded.
6. Patients with frozen shoulder will be excluded.
7. Patients with glenohumeral or acromioclavicular arthritis will be excluded.
8. Patients with an implanted pacemaker will be excluded.